Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Gov't Disowns ‘Secret’ Meetings With US On Post-Brexit Drug Pricing

Brexit And NHS Will Dominate General Election Campaign

Executive Summary

Brexit and the NHS are likely to be key issues as political parties in the UK prepare to campaign ahead of the general election in December. 

You may also be interested in...



Drug Price Impact of UK-US Trade Deal Comes Under Scrutiny

A month after the UK and the US began talks on a future free trade agreement, a new House of Lords committee says that an FTA involves risks as well as benefits, and has stakeholders to give their views on the likely impact of a deal in areas like drug pricing and the NHS.

Drug Prices ‘Not On The Table’ In UK-US Trade Deal Talks

As the UK prepares for talks on post-Brexit free trade agreements with the EU and other countries around the world, the life science industry has called for a specific pharmaceutical annex in any FTAs. 

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS141106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel